Human leukocyte antigen-B phenotype and minimal residual disease in chronic myeloid leukemia patients treated with imatinib: Is there an association?
E Hadad, A Ehsanpour, T Vosoughi… - Clinical Cancer …, 2020 - search.ebscohost.com
Background: Human leukocyte antigen (HLA) phenotype is a prognostic marker of cancer
immunotherapy, and the expression profile of its alleles is associated with therapeutic rate …
immunotherapy, and the expression profile of its alleles is associated with therapeutic rate …
Does BCR-ABL transcript type predict cytogenetic response to imatinib mesylate in chronic phase, chronic myeloid leukemia patients?
7043 Background: We prospectively studied BCR-ABL transcript type (b2a2, b3a2, e1a2
and e19a2 in 100 CML-CP patients treated with Imatinib mesylate therapy and studied their …
and e19a2 in 100 CML-CP patients treated with Imatinib mesylate therapy and studied their …
Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who …
SE Lee, SY Choi, SH Kim, HY Song, HL Yoo… - Leukemia & …, 2018 - Taylor & Francis
We conducted this study to identify the factors for predicting poor outcomes in chronic
myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR) …
myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR) …
S-phase fraction as response marker in patients with chronic myeloid leukemia
AK Tripathi, P Tripathi, R Ahmad… - Leukemia & …, 2009 - Taylor & Francis
Prognostic factors which can predict response to imatinib in patients with chronic myeloid
leukemia (CML) have been of much interest. Identification of patients who are likely to fail to …
leukemia (CML) have been of much interest. Identification of patients who are likely to fail to …
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia
L Wang, K Pearson, JE Ferguson… - British journal of …, 2003 - Wiley Online Library
Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
HX Lin, J Sjaarda, J Dyck, R Stringer… - European journal of …, 2016 - Wiley Online Library
Objectives Achieving a major molecular response (MMR) is the goal of imatinib therapy for
chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript …
chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript …
[HTML][HTML] High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With …
Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
[HTML][HTML] Assessment of BCR-ABL1 Transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with …
Abstract Abstract 1680 We studied BCR-ABL1 transcript levels in patients with CML in
chronic phase at 3, 6 and 12 months after starting imatinib to identify molecular milestones …
chronic phase at 3, 6 and 12 months after starting imatinib to identify molecular milestones …
[HTML][HTML] BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid …
Z Cai, X Jia, J Zi, H Song, S Wang, M McGrath… - Journal of …, 2020 - ncbi.nlm.nih.gov
Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase
chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early …
chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early …